Bit Capital Gmb H Akero Therapeutics, Inc. Transaction History

Bit Capital Gmb H

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2025	SELL	$11.38 - $50.33 $48,660 - $215,211	-4,276 Closed	0 $0
Q2 2023 Feb 12, 2025	BUY	$36.89 - $56.88 $86,138 - $132,814	2,335 Added 120.3%	4,276 $200 Million
Q1 2023 Feb 12, 2025	SELL	$37.27 - $50.24 $263,946 - $355,799	-7,082 Reduced 78.49%	1,941 $74.3 Million
Q4 2022 Feb 12, 2025	SELL	$33.44 - $54.8 $297,616 - $487,720	-8,900 Reduced 49.66%	9,023 $494 Million
Q3 2022 Feb 12, 2025	BUY	$10.15 - $34.05 $181,918 - $610,278	17,923 New	17,923 $610 Million

193

73.9M

210K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $2.33B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Bit Capital Gmb H, based on Form 13F filings with the SEC.

Stay updated on Bit Capital Gmb H with notifications on news.